Lenalidomide, an immunomodulatory drug often used to treat multiple myeloma, can cause hypo- or hyperthyroidism. We present a patient being treated with lenalidomide for 2 years who developed severe hypothyroidism that was complicated by rhabdomyolysis and acute kidney injury. Thyroid function tests should be serially monitored in patients taking lenalidomide.
Keywords: endocrinology; hypothyroidism; lenalidomide; multiple myeloma (Neoplasia‐ myeloma and other plasma cell dyscrasias); rhabdomyolysis.